Literature DB >> 25965312

CROI 2015: Complications of HIV Infection and Antiretroviral Therapy.

Diane V Havlir1, Judith S Currier2.   

Abstract

Noncommunicable diseases, such as cardiovascular disease, hypertension, renal and bone disease, and malignancies are an ongoing concern during the course of treated HIV disease. Research in this area continues to focus on the epidemiology and risk factors associated with these conditions, identifying the contributions of HIV-related immunopathology to specific and collective end-organ diseases, and evaluating interventions to prevent or reduce the morbidity associated with these conditions. Infectious complications of HIV, such as tuberculosis and cryptococcal disease, also continue to cause substantial morbidity and mortality; diagnosis, prevention, and treatment of these is an area of focus. The 2015 Conference on Retroviruses and Opportunistic Infections provided new insights into all of these areas.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25965312      PMCID: PMC6148904     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN: 2161-5853


  8 in total

1.  Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use them widely? Evaluation of Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-1509, and Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1488-99.

Authors:  Sheila Anne Doggrell; Kaileen Anne Lynch
Journal:  Expert Opin Biol Ther       Date:  2015-09-28       Impact factor: 4.388

2.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

3.  Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.

Authors:  Tricia H Burdo; Janet Lo; Suhny Abbara; Jeffrey Wei; Michelle E DeLelys; Fred Preffer; Eric S Rosenberg; Kenneth C Williams; Steven Grinspoon
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

4.  Plasma levels of soluble CD14 independently predict mortality in HIV infection.

Authors:  Netanya G Sandler; Handan Wand; Annelys Roque; Matthew Law; Martha C Nason; Daniel E Nixon; Court Pedersen; Kiat Ruxrungtham; Sharon R Lewin; Sean Emery; James D Neaton; Jason M Brenchley; Steven G Deeks; Irini Sereti; Daniel C Douek
Journal:  J Infect Dis       Date:  2011-01-20       Impact factor: 5.226

5.  Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection.

Authors:  Theodoros Kelesidis; Michelle A Kendall; Otto O Yang; Howard N Hodis; Judith S Currier
Journal:  J Infect Dis       Date:  2012-10-12       Impact factor: 5.226

6.  Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.

Authors:  Damalie Nakanjako; Isaac Ssinabulya; Rose Nabatanzi; Lois Bayigga; Agnes Kiragga; Moses Joloba; Pontiano Kaleebu; Andrew D Kambugu; Moses R Kamya; Rafick Sekaly; Alison Elliott; Harriet Mayanja-Kizza
Journal:  Trop Med Int Health       Date:  2015-01-06       Impact factor: 2.622

Review 7.  Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction.

Authors:  Reneé de Waal; Karen Cohen; Gary Maartens
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

8.  Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use - United States, 2013.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-10-18       Impact factor: 17.586

  8 in total
  7 in total

1.  Momordica charantia mitigates hepatic injury following adjuvant treatment with antiretroviral drugs in diabetic animal models.

Authors:  Ugochukwu Offor; Edwin C S Naidu; Oluwatosin O Ogedengbe; Peter I Aniekan; Onyemaechi O Azu
Journal:  Toxicol Res       Date:  2019-12-02

2.  Determinants of hypertension in a young adult Ugandan population in epidemiological transition-the MEPI-CVD survey.

Authors:  James Kayima; Joaniter Nankabirwa; Isaac Sinabulya; Jane Nakibuuka; Xiaofeng Zhu; Mahboob Rahman; Christopher T Longenecker; Achilles Katamba; Harriet Mayanja-Kizza; Moses R Kamya
Journal:  BMC Public Health       Date:  2015-08-28       Impact factor: 3.295

3.  Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens.

Authors:  Sandra Pinto-Cardoso; Catherine Lozupone; Olivia Briceño; Selma Alva-Hernández; Norma Téllez; Aguilar Adriana; Akio Murakami-Ogasawara; Gustavo Reyes-Terán
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

4.  Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individuals.

Authors:  Yirui Xie; Jia Sun; Li Wei; Haiyin Jiang; Caiqin Hu; Jiezuan Yang; Ying Huang; Bing Ruan; Biao Zhu
Journal:  BMC Microbiol       Date:  2021-01-06       Impact factor: 3.605

5.  Effects of viremia and CD4 recovery on gut "microbiome-immunity" axis in treatment-naïve HIV-1-infected patients undergoing antiretroviral therapy.

Authors:  Edda Russo; Giulia Nannini; Gaetana Sterrantino; Seble Tekle Kiros; Vincenzo Di Pilato; Marco Coppi; Simone Baldi; Elena Niccolai; Federica Ricci; Matteo Ramazzotti; Marco Pallecchi; Filippo Lagi; Gian Maria Rossolini; Alessandro Bartoloni; Gianluca Bartolucci; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2022-02-14       Impact factor: 5.374

Review 6.  HIV-Associated TB Syndemic: A Growing Clinical Challenge Worldwide.

Authors:  Maria Theresa Montales; Arun Chaudhury; Alexandria Beebe; Sowmya Patil; Naveen Patil
Journal:  Front Public Health       Date:  2015-12-23

7.  Rare presentation of intractable tuberculous panophthalmitis with intraocular and intraorbital abscesses: a case report.

Authors:  Sutasinee Boonsopon; Nattaporn Tesavibul; Mongkol Uiprasertkul; Supinda Leeamornsiri; Pitipol Choopong
Journal:  J Med Case Rep       Date:  2017-07-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.